Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Reaffirmed by HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $25.00 price target on the stock.

Separately, Rodman & Renshaw initiated coverage on Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They set a “buy” rating and a $9.00 price target for the company.

Milestone Pharmaceuticals Stock Performance

MIST opened at $1.49 on Monday. The company has a market cap of $79.36 million, a PE ratio of -1.19 and a beta of 1.72. The stock has a 50-day moving average of $1.46 and a 200-day moving average of $1.53. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $3.52. The company has a debt-to-equity ratio of 1.61, a quick ratio of 19.13 and a current ratio of 19.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. As a group, equities research analysts forecast that Milestone Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Lion Point Capital LP raised its holdings in Milestone Pharmaceuticals by 1.7% in the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock valued at $3,089,000 after acquiring an additional 40,000 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after acquiring an additional 10,000 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Milestone Pharmaceuticals by 177.0% in the 1st quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock valued at $30,000 after acquiring an additional 10,800 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.